DTILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends May 21
PRECISION BIOSCIENCES INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.19+0.42 (+7.28%)
Close on Oct 19, 2026
- Market cap
- $160.05M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
64.0%
18M of 28M shares
Institutional holders
95
31 new, 13 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
6 buys · 11 sales
Net sold $402.95K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Aquilo Capital Management, LLC | 791,862 | 9.90% | 13G (passive) amendment | Dec 31, 2024 |
| Tang Capital Management, LLC | 673,332 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
| Tang Capital Partners, LP | 6,400,000 | 5.20% | 13G (passive) | Jan 24, 2024 |
| Perceptive Advisors LLC | 426,293 | 5.90% | 13G (passive) amendment | Sep 30, 2024 |
| Ting Jia | 2,328,485 | 9.99% | 13G (passive) | Dec 31, 2025 |
| Empery Asset Management, LP | 2,297,781 | 9.99% | 13G (passive) | Dec 31, 2025 |
| Aberdeen Group plc | 2,138,603 | 8.88% | 13G (passive) | Dec 31, 2025 |
| Andrew Gundlach | 1,900,000 | 8.21% | 13G (passive) amendment | Dec 31, 2025 |
| Weston Nichols | 1,390,611 | 5.40% | 13G (passive) | Jul 13, 2026 |
| Matthew Smith | 1,119,311 | 9.40% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DTIL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| abrdn plc | 2,230,178 | 8.08% | $17.53M | – | 0.02% |
| Bleichroeder LP | 2,018,190 | 7.31% | $15.86M | +355,690 | 2.84% |
| Octagon Capital Advisors LP | 1,350,000 | 4.89% | $10.61M | −886,732 | 0.95% |
| Boothbay Fund Management, LLC | 1,346,004 | 4.88% | $10.58M | +279,954 | 0.14% |
| BlackRock, Inc. | 1,172,873 | 4.25% | $9.22M | +973,112 | 0.00% |
| Vanguard Capital Management LLC | 1,116,241 | 4.04% | $8.77M | +205,501 | 0.00% |
| Lynx1 Capital Management LP | 950,466 | 3.44% | $7.47M | −34,647 | 0.86% |
| Driehaus Capital Management LLC | 946,707 | 3.43% | $7.44M | −48,664 | 0.04% |
| Empery Asset Management, LP | 776,093 | 2.81% | $6.10M | −1,192,786 | 7.05% |
| Affinity Asset Advisors, LLC | 646,576 | 2.34% | $5.08M | +48,630 | 0.23% |
| Geode Capital Management, LLC | 620,981 | 2.25% | $4.88M | +333,891 | 0.00% |
| Mackenzie Financial Corp | 480,997 | 1.74% | $3.78M | New | 0.00% |
| State Street Corp | 427,325 | 1.55% | $3.36M | +354,383 | 0.00% |
| Acadian Asset Management LLC | 305,759 | 1.11% | $2.40K | +260,991 | 0.00% |
| ArrowMark Colorado Holdings LLC | 274,140 | 0.99% | $2.15M | +95,000 | 0.09% |
| Corient Private Wealth LLC | 245,058 | 0.89% | $1.93M | +101,206 | 0.00% |
| Two Sigma Investments, LP | 237,863 | 0.86% | $1.87M | −69,927 | 0.00% |
| Northern Trust Corp | 190,188 | 0.69% | $1.49M | +114,119 | 0.00% |
| JPMorgan Chase & Co | 180,452 | 0.65% | $1.43M | +180,444 | 0.00% |
| Vanguard Fiduciary Trust Co | 166,538 | 0.60% | $1.31M | +10,912 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 95 | 18M | 64.0% | 31 / 31 | 14 / 13 | 5M | 3M |
| Q1 2026 | 78 | 16M | 58.5% | 21 / 24 | 13 / 11 | 4M | 2M |
| Q4 2025 | 69 | 15M | 54.7% | 21 / 22 | 8 / 8 | 11M | 1M |
| Q3 2025 | 56 | 5M | 16.8% | 11 / 15 | 10 / 7 | 1M | 0M |
| Q2 2025 | 52 | 4M | 16.2% | 11 / 14 | 8 / 7 | 2M | 1M |
| Q1 2025 | 48 | 4M | 13.7% | 6 / 9 | 11 / 12 | 1M | 1M |
| Q4 2024 | 55 | 4M | 14.1% | 14 / 18 | 9 / 10 | 2M | 1M |
| Q3 2024 | 51 | 3M | 12.0% | 8 / 10 | 9 / 3 | 0M | 0M |
| Q2 2024 | 47 | 3M | 11.5% | 8 / 10 | 14 / 4 | 0M | 0M |
| Q1 2024 | 43 | 3M | 11.6% | 43 / 0 | 0 / 0 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of DTIL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 778,139 | 2.82% | $6.12M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 427,167 | 1.55% | $3.36M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 312,368 | 1.13% | $2.46M | 0.00% | Jun 30, 2026 |
| Meridian Contrarian Fund | 274,140 | 0.99% | $2.15M | 0.32% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 261,845 | 0.95% | $1.83M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 168,208 | 0.61% | $1.32M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 126,684 | 0.46% | $882.99K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 75,800 | 0.27% | $595.79K | 0.04% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 61,076 | 0.22% | $480.06K | 0.04% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 58,327 | 0.21% | $407.71K | 0.01% | Jul 31, 2026 |
| Jacob Discovery Fund | 52,089 | 0.19% | $363.06K | 2.26% | May 31, 2026 |
| Fidelity Total Market Index Fund | 48,562 | 0.18% | $338.48K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 37,496 | 0.14% | $261.35K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 34,175 | 0.12% | $268.62K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Value Index Fund | 33,566 | 0.12% | $263.83K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Amoroso | President and CEO, Director | 243,392 | 0.88% | Jun 3, 2026 |
| Naresh Haresh Tanna | Chief Financial Officer | 25,575 | 0.09% | Aug 3, 2026 |
| Cassandra Louise Gorsuch | Chief Scientific Officer | 16,028 | 0.06% | Aug 3, 2026 |
| Mei Zhang Lu Burris | Chielf Accounting Officer | 5,115 | 0.02% | Aug 3, 2026 |
| J. Jefferson Smith | Chief Research Officer | 129,857 | 0.47% | Jun 3, 2026 |
| John Alexander Kelly | Chief Financial Officer | 125,883 | 0.46% | Jun 3, 2026 |
| Dario Scimeca | General Counsel and Secretary | 56,457 | 0.20% | Jun 3, 2026 |
| Stanley Frankel | Director | 41,478 | 0.15% | Sep 30, 2026 |
| Geno J. Germano | Director | 47,492 | 0.17% | Sep 29, 2026 |
| Melinda Brown | Director | 45,481 | 0.16% | Sep 29, 2026 |
| Kevin Buehler | Director | 49,137 | 0.18% | Jun 5, 2026 |
| Shari Lisa Pire | Director | 35,028 | 0.13% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stanley Frankel Director | Sep 28, 2026 | Buy | +1,000 | $6.00 | $6.00K | 41,478 |
| Geno J. Germano Director | Sep 25, 2026 | Buy | +2,609 | $6.28 | $16.38K | 47,492 |
| Melinda Brown Director | Sep 25, 2026 | Buy | +1,135 | $6.27 | $7.12K | 45,481 |
| Geno J. Germano Director | May 20, 2026 | Option exercise | +21,000 | – | – | 44,883 |
| Kevin Buehler Director | May 20, 2026 | Option exercise | +21,000 | – | – | 49,137 |
| Stanley Frankel Director | May 20, 2026 | Option exercise | +21,000 | – | – | 40,478 |
| Melinda Brown Director | May 20, 2026 | Option exercise | +21,000 | – | – | 44,346 |
| Shari Lisa Pire Director | May 20, 2026 | Option exercise | +21,000 | – | – | 35,028 |
| Dario Scimeca General Counsel and Secretary | Feb 18, 2026 | Sale(10b5-1 plan) | −4,925 | $3.84 | $18.91K | 56,457 |
| J. Jefferson Smith Chief Research Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −4,925 | $3.84 | $18.91K | 121,926 |
| John Alexander Kelly Chief Financial Officer | Feb 18, 2026 | Sale(10b5-1 plan) | −8,149 | $3.84 | $31.29K | 125,883 |
| Michael Amoroso President and CEO, Director | Feb 18, 2026 | Sale(10b5-1 plan) | −20,559 | $3.84 | $78.95K | 243,392 |
| Dario Scimeca General Counsel and Secretary | Feb 17, 2026 | Option exercise | +16,667 | – | – | 61,382 |
| J. Jefferson Smith Chief Research Officer | Feb 17, 2026 | Option exercise | +16,667 | – | – | 126,851 |
| John Alexander Kelly Chief Financial Officer | Feb 17, 2026 | Option exercise | +27,584 | – | – | 134,032 |
| Michael Amoroso President and CEO, Director | Feb 17, 2026 | Option exercise | +67,797 | – | – | 263,951 |
| Michael Amoroso President and CEO, Director | Jan 22, 2026 | Sale(10b5-1 plan) | −34,799 | $4.17 | $145.11K | 196,154 |
| John Alexander Kelly Chief Financial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −15,213 | $4.03 | $61.31K | 106,448 |
| Dario Scimeca General Counsel and Secretary | Jan 21, 2026 | Sale(10b5-1 plan) | −8,854 | $4.03 | $35.68K | 44,715 |
| J. Jefferson Smith Chief Research Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −10,200 | $4.03 | $41.11K | 110,184 |
| J. Jefferson Smith Chief Research Officer | Jan 21, 2026 | Option exercise | +16,219 | – | – | 120,384 |
| John Alexander Kelly Chief Financial Officer | Jan 20, 2026 | Option exercise | +3,888 | – | – | 81,186 |
| John Alexander Kelly Chief Financial Officer | Jan 20, 2026 | Option exercise | +26,575 | – | – | 121,661 |
| John Alexander Kelly Chief Financial Officer | Jan 20, 2026 | Option exercise | +13,900 | – | – | 95,086 |
| Michael Amoroso President and CEO, Director | Jan 20, 2026 | Option exercise | +69,421 | – | – | 230,953 |
| Michael Amoroso President and CEO, Director | Jan 20, 2026 | Option exercise | +8,888 | – | – | 124,463 |
| Michael Amoroso President and CEO, Director | Jan 20, 2026 | Option exercise | +37,069 | – | – | 161,532 |
| Dario Scimeca General Counsel and Secretary | Jan 20, 2026 | Option exercise | +14,908 | – | – | 53,569 |
| Dario Scimeca General Counsel and Secretary | Jan 20, 2026 | Option exercise | +8,425 | – | – | 38,661 |
| Dario Scimeca General Counsel and Secretary | Jan 20, 2026 | Option exercise | +1,978 | – | – | 30,236 |
| J. Jefferson Smith Chief Research Officer | Jan 20, 2026 | Option exercise | +2,500 | – | – | 93,718 |
| J. Jefferson Smith Chief Research Officer | Jan 20, 2026 | Option exercise | +10,447 | – | – | 104,165 |
| Geno J. Germano Director | Dec 16, 2025 | Buy | +3,000 | $4.72 | $14.16K | 23,883 |
| Stanley Frankel Director | Dec 16, 2025 | Buy | +2,700 | $4.70 | $12.69K | 19,478 |
| Melinda Brown Director | Dec 15, 2025 | Buy | +1,381 | $4.97 | $6.86K | 23,346 |
| Dario Scimeca General Counsel and Secretary | Nov 3, 2025 | Sale(10b5-1 plan) | −665 | $6.49 | $4.32K | 28,258 |
| Michael Amoroso President and CEO, Director | Nov 3, 2025 | Sale(10b5-1 plan) | −3,409 | $6.49 | $22.12K | 115,575 |
| John Alexander Kelly Chief Financial Officer | Nov 3, 2025 | Sale(10b5-1 plan) | −1,303 | $6.49 | $8.46K | 77,298 |
| Dario Scimeca General Counsel and Secretary | Nov 2, 2025 | Option exercise | +1,835 | – | – | 28,923 |
| Michael Amoroso President and CEO, Director | Nov 2, 2025 | Option exercise | +9,444 | – | – | 118,984 |
| John Alexander Kelly Chief Financial Officer | Nov 2, 2025 | Option exercise | +3,605 | – | – | 78,601 |
| Stanley Frankel Director | Sep 26, 2025 | Buy | +2,700 | $4.97 | $13.42K | 16,778 |
| Melinda Brown Director | Sep 22, 2025 | Buy | +1,400 | $4.89 | $6.85K | 21,965 |
| John Alexander Kelly Chief Financial Officer | Jul 3, 2025 | Sale(10b5-1 plan) | −14,827 | $4.26 | $63.16K | 73,485 |
| Kevin Buehler Director | Jun 25, 2025 | Buy | +5,076 | $4.16 | $21.12K | 28,137 |
| Melinda Brown Director | Jun 25, 2025 | Buy | +1,682 | $4.14 | $6.96K | 20,565 |
| Geno J. Germano Director | May 27, 2025 | Option exercise | +9,826 | – | – | 20,883 |
| Kevin Buehler Director | May 27, 2025 | Option exercise | +9,826 | – | – | 23,061 |
| Melinda Brown Director | May 27, 2025 | Option exercise | +9,826 | – | – | 18,883 |
| Shari Lisa Pire Director | May 27, 2025 | Option exercise | +9,826 | – | – | 14,028 |
| Stanley Frankel Director | May 27, 2025 | Option exercise | +9,826 | – | – | 14,078 |
| Melinda Brown Director | Mar 26, 2025 | Buy | +1,839 | $4.75 | $8.74K | 9,057 |
| Kevin Buehler Director | Mar 26, 2025 | Buy | +4,523 | $4.67 | $21.12K | 13,235 |
| Geno J. Germano Director | Mar 25, 2025 | Buy | +3,250 | $5.30 | $17.23K | 11,057 |
| Michael Amoroso President and CEO, Director | Mar 24, 2025 | Sale(10b5-1 plan) | −964 | $5.56 | $5.36K | 109,540 |
| Michael Amoroso President and CEO, Director | Mar 21, 2025 | Option exercise | +3,417 | – | – | 110,504 |
| J. Jefferson Smith Chief Research Officer | Mar 4, 2025 | Sale(10b5-1 plan) | −154 | $4.91 | $756 | 87,805 |
| Dario Scimeca General Counsel and Secretary | Mar 4, 2025 | Sale(10b5-1 plan) | −272 | $4.91 | $1.34K | 25,000 |
| John Alexander Kelly Chief Financial Officer | Mar 3, 2025 | Option exercise | +1,702 | – | – | 86,256 |
| J. Jefferson Smith Chief Research Officer | Mar 3, 2025 | Option exercise | +519 | – | – | 87,959 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| J. Jefferson Smith Officer | Feb 18, 2026 | 4,925 | $18.93K | Feb 18, 2026 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Feb 18, 2026 | 20,559 | $79.02K | Feb 18, 2026 | Restricted Stock Vesting |
| Dario Scimeca Officer | Feb 18, 2026 | 4,925 | $18.93K | Feb 18, 2026 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Feb 18, 2026 | 8,149 | $31.32K | Feb 18, 2026 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Jan 22, 2026 | 34,799 | $145.20K | Jan 22, 2026 | Restricted Stock Vesting |
| Dario Scimeca Officer | Jan 21, 2026 | 8,854 | $35.65K | Jan 21, 2026 | Restricted Stock Vesting |
| J. Jefferson Smith Officer | Jan 21, 2026 | 10,200 | $41.07K | Jan 21, 2026 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Jan 21, 2026 | 15,213 | $61.26K | Jan 21, 2026 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Nov 3, 2025 | 1,303 | $8.46K | Nov 3, 2025 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Nov 3, 2025 | 3,409 | $22.12K | Nov 3, 2025 | Restricted Stock Vesting |
| Dario Scimeca Officer | Nov 3, 2025 | 665 | $4.32K | Nov 3, 2025 | Restricted Stock Vesting |
| John Alexander Kelly Officer | Jul 3, 2025 | 14,827 | $63.21K | Jul 3, 2025 | Restricted Stock Vesting |
| Michael Amoroso Officer, Director | Mar 24, 2025 | 964 | $5.36K | Mar 24, 2025 | Restricted Stock Vesting |
| Alan List Officer | Mar 5, 2025 | 333 | $1.68K | Mar 5, 2025 | Restricted Stock Vesting |
| J. Jefferson Smith Officer | Mar 4, 2025 | 154 | $756 | Mar 4, 2025 | Restricted Stock Vesting |